The Latest Journal Articles in Oncology

1Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapyBreast Cancer Research and Treatment, April 24, 2015  Clinical Article
2Donepezil for irradiated brain tumor survivors: A phase III randomized placebo-controlled clinical trialJournal of Clinical Oncology, April 24, 2015  Clinical Article
3Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysisJournal of Clinical Oncology, April 24, 2015  Evidence Based Medicine
4A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerAnnals of Oncology, April 24, 2015  Clinical Article
5Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general populationAnnals of Oncology, April 24, 2015  Clinical Article
6Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancerBMC Cancer, April 24, 2015  Full Text  Clinical Article
7Subgroup analyses in reporting of phase III clinical trials in solid tumorsJournal of Clinical Oncology, April 24, 2015  Clinical Article
8Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancerAnnals of Oncology, April 24, 2015  Clinical Article
9A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancerCancer Chemotherapy and Pharmacology, April 24, 2015  Clinical Article
10Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancerBreast Cancer Research and Treatment, April 24, 2015  Clinical Article
1Scientists detect lymphoma relapse by monitoring cell-free tumor DNAStanford School of Medicine News, April 24, 2015
2Pancreatic cancer breakthrough: Scientists turn cancer cells into normal cellsSanford-Burnham Medical Research Institute News, April 24, 2015
3Detecting lung cancer at an early stageRuhr-Universitaet-Bochum News, April 24, 2015
4Nih-funded research leads to approval of drug for acute radiation injuryNational Institute of Allergy and Infectious Disease - News, April 24, 2015
5More detailed findings confirm that coffee protects against breast cancer recurrenceLund University News, April 24, 2015
6Scientists discover genetic cause of deadly rare disease ‘dyskeratosis congenita’Queen Mary University of London News, April 24, 2015
7Study illuminates role of cancer drug decitabine in repairing damaged cellsPurdue University Research news, April 24, 2015
8Study sheds new light on a crucial enzyme for the immune responseUniversite de Montreal News, April 24, 2015
9Potential new target to prevent breast cancer relapseThe University of Adelaide News, April 24, 2015
10Triple negative breast cancer in African-American women has distinct differenceGeorgetown University Medical Center News, April 24, 2015

Show Me:

CHD7 associated with survival in pancreatic ductal adenocarcinoma patients receiving gemcitabine

As reported in Cancer Research, low CHD7 expression is associated with increased RFS and OS in pancreatic ductal adenocarcinoma patients receiving gemcitabine. There was no association between CHD7 expression and RFS or OS in patients who were not treated with gemcitabine.

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocIGPC is a safe and effective means of reducing the pain associated with bone metastases

Clinical Pearl from Smartest DocGenetic polymorphisms in metabolism-related genes correlate with overall survival, TTP, and disease progression in pancreatic cancer patients treated with gemcitabine

Clinical Pearl from Smartest DocIn patients with melanoma, transection and lack of residual melanoma on re-excision after transection does not influence survival.

Be Ready for Upcoming 2015 Board Exams!

Be prepared for board reviews with confidence with 1000s of board exam style questions. Prepare Here